Magnetic Resonance - Technology Information Portal Friday, 20 November 2009••
Info
  Sheets


Out-
      side
 
ADVERTISEMENT
ADVERTISEMENT

ADVERTISEMENT
ADVERTISEMENT

ADVERTISEMENT
ADVERTISEMENT

 
 'Combidex' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Combidex' found in 1 term [] and 5 definitions []
1 - 5 (of 6)     next
Result Pages : [1]  [2]
 bottom
Searchterm 'Combidex' was also found in the following service of MR-TIP.com:  
News  (5)  
 
Combidex®InfoSheet: - Contrast Agents - Intro, Overview, Characteristics, Types of, etc.MRI Resource Directory: - Contrast Agents -
 
Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes.
See also Ferumoxtran, and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Ferumoxtran, USPIO, AMI-227
DEVELOPER AMAG Pharmaceuticals, Inc.
CENTRAL MOIETY Fe3+/Fe2+
CONTRAST EFFECT T1, predominantly T2
RELAXIVITY r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO)
OSMOLALITY
CONCENTRATION
DOSAGE 2.6 mg Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION Lymph node, (MR angiography vascular, staging of RES-directed liver diseases)
DEVELOPMENT STAGE
DISTRIBUTOR
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!


Further Reading:
  Basics:
Combidex®Open this link in a new window
   by www.amagpharma.com    
Progress Report: MRI Contrast Agents and AtherosclerosisOpen this link in a new window
2006   by www.ncbi.nlm.nih.gov    
  News & More:
Ultrasmall Superparamagnetic IronOxide–enhanced MR Imaging of AtheroscleroticPlaque in Hyperlipidemic Rabbits, RUEHM ET AL Academic Radiology, Vol 9, Suppl 1, page 143(.pdf)Open this link in a new window
2002   by www.academicradiology.com       [Free, but registration is required.]
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1(.pdf)Open this link in a new window
2002
 •• There is 1 news about 'Combidex®'.
MRI Resources  
Sequences - Coils - Manufacturers - Quality Advice - - Spectroscopy
 
FerumoxtranInfoSheet: - Contrast Agents - Intro, Overview, Characteristics, Types of, etc.
 
Short name: Ami 227, generic name: Ferumoxtran, (USPIO)
Ferumoxtran is a substance of the class of ultrasmall superparamagnetic iron oxide used as a lymph node specific contrast agent for MRI.
See also Combidex®, Sinerem® and Ultrasmall Superparamagnetic Iron Oxide.
Partner(s): Cytogen Corporation, National Cancer Institute. An approvable letter was received from the U.S. Food and Drug Administration for Combidex in June 2000. Advanced Magnetics, Inc. has submitted a complete response to the approvable letter received from the U.S. Food and Drug Administration, which was accepted by the FDA and assigned a user fee goal date of March 30, 2005. In Europe, a Dossier (the European equivalent of a NDA) was submitted by Advanced Magnetics' European partner, Guerbet SA, to the European Medicines Evaluations Agency in December 1999. (Sinerem® is the brand name for this USPIO in Europe manufactured by Guerbet, Combidex® by Advanced Magnetics for the U.S. market)
Advanced Magnetics, Inc. changed its name in July 2007 to AMAG Pharmaceuticals Inc
Further Reading:
  Basics:
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1(.pdf)Open this link in a new window
2002
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast AgentsOpen this link in a new window
Sunday, 30 November 2003   by rsna2003.rsna.org    
Ultrasmall Superparamagnetic IronOxide–enhanced MR Imaging of AtheroscleroticPlaque in Hyperlipidemic Rabbits, RUEHM ET AL Academic Radiology, Vol 9, Suppl 1, page 143(.pdf)Open this link in a new window
2002   by www.academicradiology.com       [Free, but registration is required.]
In vivo MRI of human atherosclerotic plaques.(.pdf)Open this link in a new window
USPIO-enhanced Direct Thrombus MRI(.pdf)Open this link in a new window
July 2002   by www.academicradiology.com       [Free, but registration is required.]
Searchterm 'Combidex' was also found in the following service of MR-TIP.com:  
News  (5)  
 
Advanced Magnetics, Inc.MRI Resource Directory: - Developers -
 
www.amagpharma.com The company makes organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities. The development-stage company has two products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). The company's Combidex is under development as a contrast agent for lymph disease. AMAG Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for marketing approval of Ferumoxytol (formerly Code 7228) as an iron replacement therapeutic. The product is also being evaluated for MRI applications in both cardiology and oncology.
The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)		 FOR SALE FOR SALE /
DEVELOPMENT		 DEVELOPMENT
Combidex®
Feridex®
GastroMARK®
Ferumoxytol

Contact Information
MAIL AMAG Pharmaceuticals, Inc.
61 Mooney St.
Cambridge, MA 02138
USA
PHONE +1-617-497-2070
FAX +1-617-547-2445
E-MAIL contactus@amagpharma.com
ONLINE www.amagpharma.com

Further Reading:
  Basics:
Advanced Magnetics, Inc. Announces Name Change to AMAG Pharmaceuticals, Inc.Open this link in a new window
Tuesday, 24 July 2007   by salesandmarketingnetwork.com    
FerumoxytolOpen this link in a new window
   by www.amagpharma.com    
  News & More:
Advanced Magnetics' Combidex(R) to be Reviewed by FDA Oncologic Drugs Advisory CommitteeOpen this link in a new window
Tuesday, 1 February 2005   by phx.corporate-ir.net    
AMAG Pharmaceuticals, Inc. Reports on Progress Toward Commercialization and Discusses Key Activities for 2008 at 26th Annual JPMorgan Healthcare ConferenceOpen this link in a new window
Tuesday, 8 January 2008   by www.snl.com    
 •• There are 7 news about 'Advanced Magnetics, Inc.'.
MRI Resources  
Patient Information - Most Wanted - Libraries - Jobs pool - Calculation - PACS
 
Cytogen CorporationMRI Resource Directory: - Manufacturers -
 
www.cytogen.com

[This entry is marked for removal.]

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed™ I-125 and BrachySeed™ Pd-103 (two uniquely designed, next generation radioactive seed implants for the treatment of localized prostate cancer), and NMP22® BladderChek™ (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet®, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center.
A license and marketing agreement with AMAG Pharmaceuticals Inc' (formerly Advanced Magnetics), to market the functional molecular imaging agent Combidex®, was terminated in 2007.

Contact Information
MAIL Cytogen Corporation
600 College Road East, CN5308
Princeton, NJ 08540-5308
USA
PHONE +1-609-750-8201
FAX +1-609-750-8124
ONLINE www.cytogen.com


Further Reading:
  Basics:
Combidex®Open this link in a new window
   by www.amagpharma.com    
  News & More:
Cytogen Reports Fourth Quarter and Full Year 2004 ResultsOpen this link in a new window
Wednesday, 23 February 2005   by phx.corporate-ir.net    
Cytogen Reports Second Quarter 2005 Financial ResultsOpen this link in a new window
Thursday, 4 August 2005   by phx.corporate-ir.net    
 •• There are 14 news about 'Cytogen Corporation'.
Searchterm 'Combidex' was also found in the following service of MR-TIP.com:  
News  (5)  
 
Sinerem®InfoSheet: - Contrast Agents - Intro, Overview, Characteristics, Types of, etc.MRI Resource Directory: - Contrast Agents -
 
Sinerem® is the brand name (same as Combidex®) for an ultrasmall superparamagnetic iron oxide (USPIO) to detect metastatic disease in lymph nodes. Metastatic nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes.
Lymph node imaging with Sinerem® is performed 24 to 36 hours after slow infusion. Normal lymph nodes turn black post contrast, namely on T2* weighted images. Metastatic lymph nodes remain unchanged in signal intensity.
Indication and Diseases: Cancer, Imaging for diagnosis, Lymphatic disorders.
See Ferumoxtran, and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Ferumoxtran, USPIO, AMI-227
DEVELOPER AMAG Pharmaceuticals, Inc.
CENTRAL MOIETY Fe3+/Fe2+
CONTRAST EFFECT T1, T2
RELAXIVITY r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO)
OSMOLALITY
CONCENTRATION
DOSAGE 2.6 mg Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION MR angiography vascular, staging of RES-directed liver diseases, lymph nodes
DEVELOPMENT STAGE Phase III
DISTRIBUTOR
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Further Reading:
  Basics:
Progress Report: MRI Contrast Agents and AtherosclerosisOpen this link in a new window
2006   by www.ncbi.nlm.nih.gov    
Questions and Answers on the Withdrawal of the Marketing Application for SineremOpen this link in a new window
Monday, 11 February 2008   by www.medadnews.com    
  News & More:
Guerbet withdraws its European Marketing Authorisation Application for Sinerem(.pdf)Open this link in a new window
Thursday, 13 December 2007   by www.guerbet.com    
In vivo MRI of human atherosclerotic plaques.(.pdf)Open this link in a new window
CONTRAST AGENTS IN MRI(.pdf)Open this link in a new window
Guerbet withdraws its European Marketing Authorisation Application for Sinerem(.pdf)Open this link in a new window
Thursday, 13 December 2007   by www.guerbet.com    
MRI Resources  
Pathology - Shielding - MRCP - MRI Technician and Technologist Schools - Spectroscopy - MRI Physics
 
     1 - 5 (of 6)     next
Result Pages : [1]  [2]
 Random Page
 
MR-TIP     
Community   
User
Pass
Forgot your UserID/Password ?  


Do you expect MRI to get a mass market :
is already  
yes  
maybe  
not sure  
in 2050  
never  

Look
      Ups

Latest     
  News 

ADVERTISEMENT
ADVERTISEMENT


Magnetic Resonance - Technology Information Portal
Copyright © 2003 - 2009 Softways. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2009-11-16 01:58:13]